FINWIRES · TerminalLIVE
FINWIRES

ASX:HLS

4 stories mentioning ASX:HLSUpdated 33d ago

Every FINWIRES story that references ASX:HLS, newest first.

Asia

Healius Says Macquarie Group Ceases to Be a Substantial Holder

Healius (ASX:HLS) said Macquarie Group (ASX:MQG) and its controlled bodies corporate ceased to be substantial holders of the firm on Tuesday, according to a Friday Australian bourse filing.Its shares rose 2% in recent trading on Friday

ASX:HLSASX:MQG
Asia

Healius Says Macquarie Becomes Substantial Holder

Healius (ASX:HLS) said Macquarie Group (ASX:MQG) and its controlled bodies corporate acquired 5.06% voting power in the firm on Monday, becoming a substantial holder, according to a Thursday Australian bourse filing.Macquarie holds 36.7 million securities of the firm.Its shares rose over 2% in recent trading on Thursday.

ASX:HLS
Asia

Healius Issues Fiscal Year 2026 Guidance Amid Pathology Pressures; Explores Sale of Agilex Biolabs; Shares Drop 21%

Healius (ASX:HLS) said its pathology volumes grew 1.2% and revenue 3.5% in the fiscal first half, but volumes declined by 0.4% and revenue growth came in at a slower 2.4% for the 10 months to April, according to a Wednesday filing with the Australian bourse.The company now expects fiscal year underlying earnings before interest and tax of between AU$30 million and AU$35 million, per the filing.Healius' pathology labor costs will be impacted by AU$1.8 million in the fiscal fourth quarter due to the Fair Work Commission's initial findings on gender-based undervaluation. These costs increased 0.8% in the 10 months to April, compared with previous guidance of broadly flat levels for the fiscal year, the company said.It added that Australia's federal budget contains no new funding for pathology, a sector that is already under pressure and operating under an indexation freeze for most tests. The company has cut staff and closed collection centers and regional laboratories due to insufficient funding.Additionally, Healius has engaged UBS Securities Australia to help explore a potential sale of Agilex Biolabs, which operates as a standalone business within Healius. The strategic review follows "several unsolicited approaches from credible parties," the company said.Healius shares fell 21% in recent Wednesday trade and earlier hit an all-time low.

ASX:HLS
Asia

Healius Says Macquarie Ceases to Be Substantial Holder

Healius (ASX:HLS) said Macquarie Group and its controlled entities have ceased to be a substantial holder in the company on April 8, according to a Monday Australian bourse filing.The company's shares rose 1% in recent Monday trade.

ASX:HLS

Track with the FINWIRES app suite